-
Featured Authors
-
Archives
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Inside BIO Industry Analysis
Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum
With 31 (and counting) life sciences companies having already placed IPOs on the market within the first 8 months of this year and many others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market. Is it a bubble? David Thomas, director of Industry Research and Analysis at BIO took up these questions during the opening plenary lunch of the 12th Annual BIO Investor Forum. What’s his short answer? Not Read More >
Chinese In-Licensing Continues to Strengthen
Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing other forms of biotech deal-making in 2013. In fact, the number of in-licensing deals announced so far this year is more than the combined number of 2012 deals in out-licensing, JV/Alliance and M&A, according to BIO’s Industry Analysis research and GBI. This deal-making momentum bodes well for small and medium-sized biotech companies that have early-stage compounds under development in the Read More >
China’s Biotech Innovators
As the Chinese government implements policies aimed at increasing innovation in the life sciences industry, a new breed of domestic Chinese companies are structuring their corporate infrastructure to amplify innovation. Three themes are emerging from these innovative Chinese companies: the development of new business models, partnering with Western entities, and placing Chinese citizens at the helm that have advanced degrees and industrial experience from the West. As an example, consider the management and business model Read More >
The Return of the Biotech IPO
It isn’t just the volume of IPOs this summer that makes this window a victory for hibernating private biotechs and their VC backers, it’s the details of the offerings in terms of price, performance, and type of biotech making the leap onto the public stage. For the last five years we have not seen average offering prices land above expectations, but 2013 is breaking that trend. Price performance is also impressive, with a number of Read More >
Forecasted Sales Growth of Top Therapeutic Areas: Anti-Coagulants to Outpace
Although oncology has the largest market share in the therapeutics business, anti-coagulant products are expected to grow at the fastest rate among the top 15 therapeutic categories, according to a new report from EvaluatePharma. Below is a chart of future growth rates based on data from their “World Preview 2013, Outlook to 2018” report. Their data is based on analyst estimates for marketed and pipeline drugs globally. Following the anti-coagulants are oncology and diabetes drugs Read More >
